The medical device outlook across the Asia-Pacific remains highly positive as hospitals continue increasing investments in diagnostic systems, imaging equipment, […]
Breast cancer continues to be one of the most diagnosed cancers among women worldwide, and early screening remains one of
Novartis is entering a new phase of growth powered by blockbuster cancer medicines, radioligand therapy innovation, and precision oncology expansion.
The global pharmaceutical CXO industry is no longer driven only by large drug companies. Behind many blockbuster medicines, vaccines, biologics,
Gilead Sciences Is Expanding Aggressively Beyond Traditional Oncology Gilead Sciences remains one of the strongest revenue generators in oncology cell
The biotechnology industry has moved far beyond traditional pharma. Today, it is a high-tech ecosystem powered by gene editing, mRNA
The pharmaceutical industry in 2025–2026 is increasingly being shaped by a “winner-takes-most” innovation cycle, where a small group of high-impact
Cell & Gene Therapy in 2026 is no longer an experimental corner of biotechnology.It is rapidly becoming a large-scale industrial